Möchten Sie immer auf dem neuesten Stand bleiben?

NEW YORK, Sept. 11, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, announced today that the Company has entered into an exclusive license...

NEW YORK, Sept. 9, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its...

NEW YORK, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Dear NeoStem Shareholders, We believe that cell therapy will play a large role in changing the natural history of diseases as breakthrough therapies...

NEW YORK, Aug. 20, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, announced today that Dr. Hans Keirstead, President, NeoStem Oncology, will...

NEW YORK, Aug. 7, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, today provided an update on the progress of its business and reported second...

NEW YORK, July 14, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, announced today that Frost & Sullivan has awarded the Company its 2014...

NEW YORK, July 8, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, announced today the appointment of Steven M. Klosk to its Board of...

NEW YORK, June 30, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, announced today that two of its leading cancer immunotherapy experts, Dr....

NEW YORK, June 23, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, announced today that it is set to join the broad-market Russell Global,...

-- Preliminary Data Indicate Safety and Tolerability in Adult Patients and Complement Recently Published 12-Month Data Indicating Feasibility and Potential Efficacy in Children With T1DM -- --...